19 Jun 2024
12:00 AM
AGM
Announcement Date: 19 Jun, 2024
10 Dec 2024
12:00 AM
EGM
16 Jan 2025
12:00 AM
Board Meeting
Agenda : Audited Result
31 Jan 2025
12:00 AM
Dividend
Dividend Amount: 10.5
Record Date: 06 Feb, 2025
An interim dividend of ₹10.50 on the face value per share for FY25 has been declared.
Sun Pharma has bolstered its speciality pipeline with a partnership with Philogen to commercialise late-stage candidate Fibromun.
The US Food and Drug Administration (USFDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets, according to a regulatory filing.
IMVEXXY is a vaginal insert designed to lessen pain during sexual activity after menopause which is manufactured by Mayne Pharma.
The warning letter detailed substantial violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
